Tower Research Capital LLC (TRC) - ADAPTIMMUNE THERAPEUTICS PLC ownership

ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 46 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q3 2016. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of ADAPTIMMUNE THERAPEUTICS PLC
ValueSharesWeighting
Q3 2023$6,269
-57.8%
8,037
-50.0%
0.00%
Q2 2023$14,868
+114269.2%
16,074
+31.0%
0.00%
Q1 2023$13
+8.3%
12,272
+53.6%
0.00%
Q4 2022$12
-100.0%
7,988
-73.3%
0.00%
-100.0%
Q3 2022$32,000
-36.0%
29,870
+1.7%
0.00%0.0%
Q2 2022$50,000
+400.0%
29,384
+523.5%
0.00%
Q1 2022$10,000
-54.5%
4,713
-20.5%
0.00%
Q4 2021$22,000
-53.2%
5,928
-34.7%
0.00%
-100.0%
Q3 2021$47,000
+161.1%
9,079
+114.1%
0.00%
Q2 2021$18,000
-40.0%
4,240
-25.3%
0.00%
-100.0%
Q1 2021$30,000
+114.3%
5,675
+111.5%
0.00%
Q4 2020$14,000
-46.2%
2,683
-72.0%
0.00%
-100.0%
Q1 2020$26,0009,591
+5820.4%
0.00%
Q4 2019$0
-100.0%
162
-99.2%
0.00%
-100.0%
Q3 2019$32,00021,472
+21372.0%
0.00%
Q2 2019$0
-100.0%
100
-98.4%
0.00%
-100.0%
Q1 2019$27,000
+285.7%
6,390
+1188.3%
0.00%
+100.0%
Q3 2018$7,000
-69.6%
496
-74.7%
0.00%0.0%
Q2 2018$23,000
-37.8%
1,961
-41.0%
0.00%
-66.7%
Q1 2018$37,000
+15.6%
3,321
-31.1%
0.00%
-25.0%
Q4 2017$32,000
+100.0%
4,822
+31.6%
0.00%
+100.0%
Q2 2017$16,000
+1500.0%
3,663
+1171.9%
0.00%
Q4 2016$1,000
-90.9%
288
-81.3%
0.00%
-100.0%
Q3 2016$11,000
+450.0%
1,537
+638.9%
0.00%
Q2 2016$2,0002080.00%
Other shareholders
ADAPTIMMUNE THERAPEUTICS PLC shareholders Q3 2016
NameSharesValueWeighting ↓
Syncona Portfolio Ltd 1,377,294$1,501,2502.44%
NEA Management Company, LLC 17,079,779$18,616,9581.29%
Endurant Capital Management LP 1,660,835$1,810,3100.93%
Matrix Capital Management Company, LP 38,974,185$42,481,8620.58%
Long Focus Capital Management, LLC 5,435,439$5,924,6290.34%
PFM Health Sciences, LP 5,992,571$6,531,9020.29%
Key Client Fiduciary Advisors, LLC 321,155$350,0590.22%
DAFNA Capital Management LLC 351,064$382,6600.12%
Rock Springs Capital Management LP 2,787,845$3,038,7510.07%
Baker Brothers Advisors 9,830,877$10,715,6560.06%
View complete list of ADAPTIMMUNE THERAPEUTICS PLC shareholders